- Trial phase
- Not stated
- Time to market
- unknown, no clinical or regulatory stage could be verified
- Why 1/10
- No dated catalyst exists for ALN-2232 in the next ~12 months, the molecule has no identifiable clinical trial, regulatory filing, PDUFA, or public disclosure in any source retrieved this session, so the impact score sits at the bottom of the scale.
Do not trade ALNY on the basis of ALN-2232, there is no verifiable evidence this candidate is a disclosed clinical-stage program, and it cannot be distinguished from an early/undisclosed preclinical code or a data-entry artifact. Watch Alnylam's official pipeline disclosures (10-K/10-Q, investor day) for any first mention of ALN-2232 before assigning it any value; company-level catalysts that ARE documented (e.g., Regeneron's cemdisiran NDA submission for generalized myasthenia gravis on 2026-04-30) are unrelated to this code.
Price Chart
Executive Summary
ALN-2232 could not be verified as a real, disclosed Alnylam program by any means available this session. The sponsor ticker is verified as ALNY (Alnylam Pharmaceuticals, Inc., Nasdaq, CIK 1178670), a large-cap with strong analyst coverage (mean price target $427.61 vs. ~$204 share price at 2026-07-31, per local snapshot) but a sharply beaten-down stock (-31.9% 1-month, composite quant score -59). Since no verifiable information about this specific molecule exists, the drug itself merits a neutral rating and minimal impact score until Alnylam publicly discloses it.
How It Works
Cannot be stated from evidence: no source retrieved this session describes what ALN-2232 targets or how it works. For context only: the developer, Alnylam Pharmaceuticals, is a Nasdaq-listed biopharma whose documented pipeline in SecBot's data centers on RNAi-style medicines for cardiovascular and rare diseases (e.g., zilebesiran for hypertension, patisiran for ATTR amyloidosis, cemdisiran for myasthenia gravis). None of those documented programs carries the ALN-2232 code.
Trial Status
No clinical trial records exist for ALN-2232 in the local ClinicalTrials.gov-backed dataset (searched by drug name, ticker ALNY, and free text) or in FDA/local catalyst datasets.
The Two-Sided Case
Upcoming Catalysts
- None identifiable for ALN-2232 itself (no trial, filing, or readout date exists in any retrieved source).
- Company-level (unrelated to this drug): FDA decision path on Regeneron-submitted cemdisiran NDA for generalized myasthenia gravis (submitted 2026-04-30 per local catalyst record); quarterly earnings; any future Alnylam pipeline update that might disclose ALN-2232.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report